{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T00:41:28Z","timestamp":1784421688738,"version":"3.55.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T00:00:00Z","timestamp":1669075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T00:00:00Z","timestamp":1669075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s11899-022-00682-4","type":"journal-article","created":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T05:13:38Z","timestamp":1669180418000},"page":"306-318","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The Role of Belantamab Mafodotin, Selinexor, and Melflufen in Multiple Myeloma"],"prefix":"10.1007","volume":"17","author":[{"given":"Arleigh","family":"McCurdy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7201-4642","authenticated-orcid":false,"given":"Alissa","family":"Visram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,22]]},"reference":[{"key":"682_CR1","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1182\/blood-2019-124825","volume":"134","author":"M-V Mateos","year":"2019","unstructured":"Mateos M-V, et al. Clinical activity of melflufen in patients with triple-class refractory multiple myeloma and poor-risk features in an updated analysis of HORIZON (OP-106), a phase 2 study in patients with relapsed\/refractory multiple myeloma refractory to pomalidomide and\/or daratumumab. Blood. 2019;134:1883\u20131883. https:\/\/doi.org\/10.1182\/blood-2019-124825.","journal-title":"Blood"},{"key":"682_CR2","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1016\/s2352-3026(21)00381-1","volume":"9","author":"FH Schjesvold","year":"2022","unstructured":"Schjesvold FH, et al. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study. Lancet Haematol. 2022;9:e98\u2013110. https:\/\/doi.org\/10.1016\/s2352-3026(21)00381-1.","journal-title":"Lancet Haematol"},{"key":"682_CR3","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa1903455","volume":"381","author":"A Chari","year":"2019","unstructured":"Chari A, et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med. 2019;381:727\u201338. https:\/\/doi.org\/10.1056\/NEJMoa1903455.","journal-title":"N Engl J Med"},{"key":"682_CR4","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1182\/blood-2018-06-858852","volume":"132","author":"NJ Bahlis","year":"2018","unstructured":"Bahlis NJ, et al. Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma. Blood. 2018;132:2546\u201354. https:\/\/doi.org\/10.1182\/blood-2018-06-858852.","journal-title":"Blood"},{"key":"682_CR5","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/s0140-6736(20)32292-3","volume":"396","author":"S Grosicki","year":"2020","unstructured":"Grosicki S, et al. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet. 2020;396:1563\u201373. https:\/\/doi.org\/10.1016\/s0140-6736(20)32292-3.","journal-title":"Lancet"},{"key":"682_CR6","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1016\/s1470-2045(18)30576-x","volume":"19","author":"S Trudel","year":"2018","unstructured":"Trudel S, et al. Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. Lancet Oncol. 2018;19:1641\u201353. https:\/\/doi.org\/10.1016\/s1470-2045(18)30576-x.","journal-title":"Lancet Oncol"},{"key":"682_CR7","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41408-019-0196-6","volume":"9","author":"S Trudel","year":"2019","unstructured":"Trudel S, et al. Antibody-drug conjugate, GSK2857916, in relapsed\/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study. Blood Cancer J. 2019;9:37. https:\/\/doi.org\/10.1038\/s41408-019-0196-6.","journal-title":"Blood Cancer J"},{"key":"682_CR8","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/s1470-2045(19)30788-0","volume":"21","author":"S Lonial","year":"2020","unstructured":"Lonial S, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21:207\u201321. https:\/\/doi.org\/10.1016\/s1470-2045(19)30788-0.","journal-title":"Lancet Oncol"},{"key":"682_CR9","doi-asserted-by":"publisher","first-page":"4198","DOI":"10.1002\/cncr.33809","volume":"127","author":"S Lonial","year":"2021","unstructured":"Lonial S, et al. Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study. Cancer. 2021;127:4198\u2013212. https:\/\/doi.org\/10.1002\/cncr.33809.","journal-title":"Cancer"},{"key":"682_CR10","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","volume":"123","author":"YT Tai","year":"2014","unstructured":"Tai YT, et al. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014;123:3128\u201338. https:\/\/doi.org\/10.1182\/blood-2013-10-535088.","journal-title":"Blood"},{"key":"682_CR11","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41408-021-00494-4","volume":"11","author":"S Lonial","year":"2021","unstructured":"Lonial S, et al. Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM). Blood Cancer J. 2021;11:103. https:\/\/doi.org\/10.1038\/s41408-021-00494-4.","journal-title":"Blood Cancer J"},{"key":"682_CR12","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1182\/blood-2019-129893","volume":"134","author":"K Weisel","year":"2019","unstructured":"Weisel K, et al. Dreamm-3: a phase 3, open-label, randomized study to evaluate the efficacy and safety of belantamab mafodotin (GSK2857916) monotherapy compared with pomalidomide plus low-dose dexamethasone (Pom\/Dex) in participants with relapsed\/refractory multiple myeloma (RRMM). Blood. 2019;134:1900\u20131900. https:\/\/doi.org\/10.1182\/blood-2019-129893.","journal-title":"Blood"},{"key":"682_CR13","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1182\/blood-2021-147101","volume":"138","author":"S Trudel","year":"2021","unstructured":"Trudel S, et al. Part 1 results of a dose-finding study of belantamab mafodotin in combination with pomalidomide and dexamethasone for the treatment of relapsed\/refractory multiple myeloma (RRMM). Blood. 2021;138:1653\u20131653. https:\/\/doi.org\/10.1182\/blood-2021-147101.","journal-title":"Blood"},{"key":"682_CR14","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1182\/blood-2020-139785","volume":"136","author":"S Trudel","year":"2020","unstructured":"Trudel S, et al. DREAMM-8: a phase III study of the efficacy and safety of belantamab mafodotin with pomalidomide and dexamethasone (B-Pd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in patients with relapsed\/refractory multiple myeloma (RRMM). Blood. 2020;136:4\u20134. https:\/\/doi.org\/10.1182\/blood-2020-139785.","journal-title":"Blood"},{"key":"682_CR15","unstructured":"Nooka A, et al. DREAMM-4: evaluating safety and clinical activity of belantamab mafodotin (belamaf) in combination with pembrolizumab in patients with relapsed\/refractory multiple myeloma. Hematol Rep. 2020;12."},{"key":"682_CR16","doi-asserted-by":"publisher","first-page":"8018","DOI":"10.1200\/JCO.2022.40.16_suppl.8018","volume":"40","author":"A Suvannasankha","year":"2022","unstructured":"Suvannasankha A, et al. Safety and clinical activity of belantamab mafodotin with pembrolizumab in patients with relapsed\/refractory multiple myeloma (RRMM): DREAMM-4 Study. J Clin Oncol. 2022;40:8018\u20138018. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.8018.","journal-title":"J Clin Oncol"},{"key":"682_CR17","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.2217\/fon-2020-1269","volume":"17","author":"AK Nooka","year":"2021","unstructured":"Nooka AK, et al. Belantamab mafodotin in combination with novel agents in relapsed\/refractory multiple myeloma: DREAMM-5 study design. Future Oncol. 2021;17:1987\u20132003. https:\/\/doi.org\/10.2217\/fon-2020-1269.","journal-title":"Future Oncol"},{"key":"682_CR18","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1182\/blood-2021-152662","volume":"138","author":"NS Callander","year":"2021","unstructured":"Callander NS, et al. DREAMM-5 study: investigating the synergetic effects of belantamab mafodotin plus inducible T-cell co-stimulator agonist (aICOS) combination therapy in patients with relapsed\/refractory multiple myeloma. Blood. 2021;138:897\u2013897. https:\/\/doi.org\/10.1182\/blood-2021-152662.","journal-title":"Blood"},{"key":"682_CR19","doi-asserted-by":"publisher","first-page":"8019","DOI":"10.1200\/JCO.2022.40.16_suppl.8019","volume":"40","author":"S Lonial","year":"2022","unstructured":"Lonial S, et al. Synergistic effects of low-dose belantamab mafodotin in combination with a gamma-secretase inhibitor (nirogacestat) in patients with relapsed\/refractory multiple myeloma (RRMM): DREAMM-5 study. J Clin Oncol. 2022;40:8019\u20138019. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.8019.","journal-title":"J Clin Oncol"},{"key":"682_CR20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1182\/blood-2020-139332","volume":"136","author":"R Popat","year":"2020","unstructured":"Popat R, et al. DREAMM-6: safety, tolerability and clinical activity of belantamab mafodotin (belamaf) in combination with bortezomib\/dexamethasone (BorDex) in relapsed\/refractory multiple myeloma (RRMM). Blood. 2020;136:19\u201320. https:\/\/doi.org\/10.1182\/blood-2020-139332.","journal-title":"Blood"},{"key":"682_CR21","doi-asserted-by":"publisher","first-page":"8017","DOI":"10.1200\/JCO.2022.40.16_suppl.8017","volume":"40","author":"H Quach","year":"2022","unstructured":"Quach H, et al. Safety and clinical activity of belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed\/refractory multiple myeloma (RRMM): DREAMM-6 arm-A interim analysis. J Clin Oncol. 2022;40:8017\u20138017. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.8017.","journal-title":"J Clin Oncol"},{"key":"682_CR22","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1182\/blood-2020-139181","volume":"136","author":"RM Rifkin","year":"2020","unstructured":"Rifkin RM, et al. DREAMM-7: a phase III study of the efficacy and safety of belantamab mafodotin (belamaf) with bortezomib, and dexamethasone (B-Vd) in patients with relapsed\/refractory multiple myeloma (RRMM). Blood. 2020;136:53\u20134. https:\/\/doi.org\/10.1182\/blood-2020-139181.","journal-title":"Blood"},{"key":"682_CR23","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1182\/blood-2021-152241","volume":"138","author":"E Terpos","year":"2021","unstructured":"Terpos E, et al. A phase 1\/2, dose and schedule evaluation study to investigate the safety and clinical activity of belantamab mafodotin administered in combination with lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma. Blood. 2021;138:2736\u20132736. https:\/\/doi.org\/10.1182\/blood-2021-152241.","journal-title":"Blood"},{"key":"682_CR24","doi-asserted-by":"publisher","first-page":"2738","DOI":"10.1182\/blood-2021-153315","volume":"138","author":"SZ Usmani","year":"2021","unstructured":"Usmani SZ, et al. DREAMM-9: phase I study of belantamab mafodotin plus standard of care in patients with transplant-ineligible newly diagnosed multiple myeloma. Blood. 2021;138:2738\u20132738. https:\/\/doi.org\/10.1182\/blood-2021-153315.","journal-title":"Blood"},{"key":"682_CR25","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1089\/jop.2015.0064","volume":"31","author":"JS Eaton","year":"2015","unstructured":"Eaton JS, Miller PE, Mannis MJ, Murphy CJ. Ocular adverse events associated with antibody-drug conjugates in human clinical trials. J Ocul Pharmacol Ther. 2015;31:589\u2013604. https:\/\/doi.org\/10.1089\/jop.2015.0064.","journal-title":"J Ocul Pharmacol Ther"},{"key":"682_CR26","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1158\/0008-5472.Can-17-3202","volume":"78","author":"H Zhao","year":"2018","unstructured":"Zhao H, et al. Modulation of macropinocytosis-mediated internalization decreases ocular toxicity of antibody-drug conjugates. Cancer Res. 2018;78:2115\u201326. https:\/\/doi.org\/10.1158\/0008-5472.Can-17-3202.","journal-title":"Cancer Res"},{"key":"682_CR27","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s40123-020-00280-8","volume":"9","author":"AV Farooq","year":"2020","unstructured":"Farooq AV, et al. Corneal epithelial findings in patients with multiple myeloma treated with antibody-drug conjugate belantamab mafodotin in the pivotal, randomized, DREAMM-2 study. Ophthalmol Ther. 2020;9:889\u2013911. https:\/\/doi.org\/10.1007\/s40123-020-00280-8.","journal-title":"Ophthalmol Ther"},{"key":"682_CR28","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18298","author":"JP Abeykoon","year":"2022","unstructured":"Abeykoon JP, et al. Impact of belantamab mafodotin-induced ocular toxicity on outcomes of patients with advanced multiple myeloma. Br J Haematol. 2022. https:\/\/doi.org\/10.1111\/bjh.18298.","journal-title":"Br J Haematol"},{"key":"682_CR29","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1158\/1535-7163.Mct-15-0488","volume":"15","author":"S Rosebeck","year":"2016","unstructured":"Rosebeck S, et al. Synergistic myeloma cell death via novel intracellular activation of caspase-10-dependent apoptosis by carfilzomib and selinexor. Mol Cancer Ther. 2016;15:60\u201371. https:\/\/doi.org\/10.1158\/1535-7163.Mct-15-0488.","journal-title":"Mol Cancer Ther"},{"key":"682_CR30","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1080\/14656566.2017.1340942","volume":"18","author":"K Podar","year":"2017","unstructured":"Podar K, Pecherstorfer M. Current and developing synthetic pharmacotherapy for treating relapsed\/refractory multiple myeloma. Expert Opin Pharmacother. 2017;18:1061\u201379. https:\/\/doi.org\/10.1080\/14656566.2017.1340942.","journal-title":"Expert Opin Pharmacother"},{"key":"682_CR31","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/leu.2017.329","volume":"32","author":"CS Chim","year":"2018","unstructured":"Chim CS, et al. Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. Leukemia. 2018;32:252\u201362. https:\/\/doi.org\/10.1038\/leu.2017.329.","journal-title":"Leukemia"},{"key":"682_CR32","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1038\/leu.2013.172","volume":"27","author":"J Schmidt","year":"2013","unstructured":"Schmidt J, et al. Genome-wide studies in multiple myeloma identify XPO1\/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276. Leukemia. 2013;27:2357\u201365. https:\/\/doi.org\/10.1038\/leu.2013.172.","journal-title":"Leukemia"},{"key":"682_CR33","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1182\/blood.V126.23.258.258","volume":"126","author":"C Chen","year":"2015","unstructured":"Chen C, et al. Safety, efficacy, and determination of the recommended phase 2 dose for the oral selective inhibitor of nuclear export (SINE) selinexor (KPT-330). Blood. 2015;126:258\u2013258. https:\/\/doi.org\/10.1182\/blood.V126.23.258.258.","journal-title":"Blood"},{"key":"682_CR34","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1200\/jco.2017.75.5207","volume":"36","author":"DT Vogl","year":"2018","unstructured":"Vogl DT, et al. Selective inhibition of nuclear export with oral selinexor for treatment of relapsed or refractory multiple myeloma. J Clin Oncol. 2018;36:859\u201366. https:\/\/doi.org\/10.1200\/jco.2017.75.5207.","journal-title":"J Clin Oncol"},{"key":"682_CR35","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/bjh.15969","volume":"186","author":"AJ Jakubowiak","year":"2019","unstructured":"Jakubowiak AJ, et al. Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed\/refractory multiple myeloma. Br J Haematol. 2019;186:549\u201360. https:\/\/doi.org\/10.1111\/bjh.15969.","journal-title":"Br J Haematol"},{"key":"682_CR36","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.clml.2019.12.013","volume":"20","author":"M Salcedo","year":"2020","unstructured":"Salcedo M, et al. Phase I study of selinexor, ixazomib, and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2020;20:198\u2013200. https:\/\/doi.org\/10.1016\/j.clml.2019.12.013.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"682_CR37","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1182\/blood-2021-148759","volume":"138","author":"DJ White","year":"2021","unstructured":"White DJ, et al. Once weekly oral selinexor, pomalidomide, and dexamethasone in relapsed refractory multiple myeloma. Blood. 2021;138:2748\u20132748. https:\/\/doi.org\/10.1182\/blood-2021-148759.","journal-title":"Blood"},{"key":"682_CR38","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1038\/s41375-020-0756-6","volume":"34","author":"M Gavriatopoulou","year":"2020","unstructured":"Gavriatopoulou M, et al. Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. Leukemia. 2020;34:2430\u201340. https:\/\/doi.org\/10.1038\/s41375-020-0756-6.","journal-title":"Leukemia"},{"key":"682_CR39","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.1158\/1078-0432.Ccr-12-3752","volume":"19","author":"D Chauhan","year":"2013","unstructured":"Chauhan D, et al. In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells. Clin Cancer Res. 2013;19:3019\u201331. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-12-3752.","journal-title":"Clin Cancer Res"},{"key":"682_CR40","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/bjh.14065","volume":"174","author":"A Ray","year":"2016","unstructured":"Ray A, et al. A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells. Br J Haematol. 2016;174:397\u2013409. https:\/\/doi.org\/10.1111\/bjh.14065.","journal-title":"Br J Haematol"},{"key":"682_CR41","doi-asserted-by":"publisher","first-page":"e395","DOI":"10.1016\/s2352-3026(20)30044-2","volume":"7","author":"PG Richardson","year":"2020","unstructured":"Richardson PG, et al. Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1\u20132 study. Lancet Haematol. 2020;7:e395\u2013407. https:\/\/doi.org\/10.1016\/s2352-3026(20)30044-2.","journal-title":"Lancet Haematol"},{"key":"682_CR42","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1200\/jco.20.02259","volume":"39","author":"PG Richardson","year":"2021","unstructured":"Richardson PG, et al. Melflufen and dexamethasone in heavily pretreated relapsed and refractory multiple myeloma. J Clin Oncol. 2021;39:757\u201367. https:\/\/doi.org\/10.1200\/jco.20.02259.","journal-title":"J Clin Oncol"},{"key":"682_CR43","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1182\/blood-2018-99-113095","volume":"132","author":"P Richardson","year":"2018","unstructured":"Richardson P, et al. OP-106 Horizon \u2014 melflufen therapy for RRMM patients refractory to daratumumab and\/or pomalidomide; updated results and first report on PFS. Blood. 2018;132:600\u2013600. https:\/\/doi.org\/10.1182\/blood-2018-99-113095.","journal-title":"Blood"},{"key":"682_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2022.101374","volume":"18","author":"T Olivier","year":"2022","unstructured":"Olivier T, Prasad V. The approval and withdrawal of melphalan flufenamide (melflufen): implications for the state of the FDA. Transl Oncol. 2022;18: 101374. https:\/\/doi.org\/10.1016\/j.tranon.2022.101374.","journal-title":"Transl Oncol"},{"key":"682_CR45","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/01.HS9.0000560796.93881.5c","volume":"3","author":"S Bringhen","year":"2019","unstructured":"Bringhen S, et al. PF628 O-12-M1: an evaluation of time to next treatment in melflufen and dexamethasone-treated patients with relapsed\/refractory multiple myeloma. HemaSphere. 2019;3:267. https:\/\/doi.org\/10.1097\/01.HS9.0000560796.93881.5c.","journal-title":"HemaSphere"},{"key":"682_CR46","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1182\/blood.V130.Suppl_1.1841.1841","volume":"130","author":"M-V Mateos","year":"2017","unstructured":"Mateos M-V, et al. Melflufen therapy for relapsed refractory multiple myeloma (RRMM) patients refractory to daratumumab and\/or pomalidomide: a report on early efficacy. Blood. 2017;130:1841\u20131841. https:\/\/doi.org\/10.1182\/blood.V130.Suppl_1.1841.1841.","journal-title":"Blood"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-022-00682-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-022-00682-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-022-00682-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T20:06:15Z","timestamp":1744142775000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-022-00682-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,22]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["682"],"URL":"https:\/\/doi.org\/10.1007\/s11899-022-00682-4","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,22]]},"assertion":[{"value":"11 September 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Arleigh McCurdy has received an honorarium for advisory boards for GSK and Forus Therapeutics. Alissa Visram has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}